Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|
All Comparisons

MOTS-c vs Retatrutide

Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.

MOTS-c: DRetatrutide: B
AttributeMOTS-cRetatrutide
CategoryMetabolic / MitochondrialMetabolic / Triple Agonist
Evidence RatingD — PreclinicalB — Phase III / NDA Filed
Clinical StatusResearch-only / No human clinical trials completed (Phase 1 of analog CB4211 only)Phase 3 clinical trials (Eli Lilly TRIUMPH program)
MechanismMOTS-c activates AMPK by inhibiting the folate cycle, causing accumulation of AICAR (an AMP analog). Activated AMPK shifts cells into energy-efficient mode: enhancing glucose uptake, fatty-acid oxidation, and mitochondrial respiration while downregulating fat storage and gluconeogenesis. Under stres...Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon (increases energy expenditure, fat oxidation, thermogenesis). This triple synergy combines reduced cal...
Half-LifeSeveral hours; tissue effects may persist longer~6 days (allows once-weekly dosing)
Bioavailability—SC injection
Molecular Weight~2174.6 g/mol—
WADA StatusNot ListedNot Prohibited
Research Half-LifeSeveral hours; tissue effects may persist longer~6 days (allows once-weekly dosing)
Key Use Cases
  • Metabolic Health
  • Anti-Aging
  • Weight Management
  • Metabolic Health
Safety Concerns
  • No adverse effects reported in preclinical animal studies
  • Human tolerability is completely unknown for native MOTS-c (no completed human trials)
  • Modified analog CB4211 showed good tolerability in Phase 1
  • GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate
  • GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose)
  • Dose-dependent heart rate increases peaking at 24 weeks, declining thereafter
Contraindications
  • No established contraindications due to absence of human clinical data
  • Caution in diabetics on glucose-lowering medication (potential additive hypoglycemia based on mechanism)
  • Pregnancy and breastfeeding (no data)
  • Active cancer (AMPK modulation has complex effects on tumor biology)
  • Not yet established -- product is investigational
  • Likely similar to GLP-1 class: personal/family history of medullary thyroid carcinoma, MEN2 (precautionary)
  • Pregnancy (based on GLP-1 class)
  • Monitoring recommended for muscle mass, bone density, GI motility per GLP-1 class concerns
Regulatory (US)Not FDA-approved. Removed from FDA Category 2 on April 15, 2026. PCAC review scheduled July 23-24, 2026. Research chemical.Not FDA-approved. Phase 3 TRIUMPH program ongoing (Eli Lilly). TRIUMPH-4 reported 28.7% body weight loss at 12 mg over 68 weeks. Seven Phase 3 readouts expected in 2026. Regulatory submission expected 2026; approval anticipated 2027-2028.

Research Material Specifications

Catalog specifications for the corresponding research materials, including batch documentation coverage.

SpecificationMOTS-cRetatrutide
Purity Standard≥98%≥98%
CAS Number1627580-64-62381089-83-2
Molecular FormulaC₁₀₁H₁₅₂N₂₈O₂₂S₂C₂₂₅H₃₄₈N₆₀O₆₈S₂
Available Formats20mg, 10mg20mg, 10mg, 5mg, 30mg
Batch COAs Published——
Stock StatusIn stockIn stock

Availability at Volta Peptides

MOTS-C 20mg

≥98% purity · HPLC verified · Restocking

$42.63

Retatrutide 20mg

≥98% purity · HPLC verified · In stock

$78.76

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

All ComparisonsBrowse Catalog

Your Cart

Your cart is empty

Browse our catalog to add research compounds.